Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
GlobalRPh RX List - PRETOMANID
Product / population
Pretomanid - tablets in a combination tuberculosis regimen; selected renal passages, not a complete prescribing monograph.
Renal method
Qualitative renal statement; no numerical renal-function threshold inferred.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-09
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
GlobalRPh-hosted RX List · Pretomanid - tablets in a combination tuberculosis regimen; selected renal passages, not a complete prescribing monograph.
Renal method: Qualitative renal statement; no numerical renal-function threshold inferred. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-09
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The effect of renal impairment on pretomanid safety, efficacy and pharmacokinetics is unknown. The source also states that the pretomanid/bedaquiline/linezolid combination has not established safety and effectiveness in renal impairment. This is an evidence gap, not a numerical dose reduction or proof of suitability. Each companion drug and the tuberculosis regimen requires its own review; no dialysis regimen is inferred.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.